Viatris Inc. (VTRS) 10-Year Financial Performance & Capital Metrics

VTRS • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

AboutViatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.Show more

Revenue $14.74B -4.5%
EBITDA $2.9B -17.2%
Net Income -$634M -1259.4%
EPS (Diluted) -0.53 -1270.0%
Gross Margin 38.15% -8.6%
EBITDA Margin 19.7% -13.3%
Operating Margin 0.07% -98.6%
Net Margin -4.3% -1313.4%
ROE -3.24% -1331.5%
ROIC 0.02% -98.5%
Debt/Equity 0.77 -14.5%
Interest Coverage 0.02 -98.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy dividend yield of 3.8%
✓Trading near 52-week high
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak 3Y average ROE of 2.3%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.68%

5Y5.09%

3Y-6.25%

TTM-6.14%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-317.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-319.92%

ROCE

10Y Avg2.87%

5Y Avg0.98%

3Y Avg1.84%

Latest0.03%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.43B	11.08B	11.91B	11.43B	11.5B	11.95B	17.89B	16.26B	15.43B	14.74B
Revenue Growth %	0.22%	0.17%	0.08%	-0.04%	0.01%	0.04%	0.5%	-0.09%	-0.05%	-0.04%
Cost of Goods Sold+	5.21B	6.38B	7.12B	7.43B	7.6B	8.15B	12.31B	9.77B	8.99B	9.12B
COGS % of Revenue	0.55%	0.58%	0.6%	0.65%	0.66%	0.68%	0.69%	0.6%	0.58%	0.62%
Gross Profit+	4.22B	4.7B	4.78B	4B	3.9B	3.8B	5.58B	6.5B	6.44B	5.62B
Gross Margin %	0.45%	0.42%	0.4%	0.35%	0.34%	0.32%	0.31%	0.4%	0.42%	0.38%
Gross Profit Growth %	0.2%	0.11%	0.02%	-0.16%	-0.03%	-0.03%	0.47%	0.17%	-0.01%	-0.13%
Operating Expenses+	2.76B	4B	3.35B	3.1B	3.18B	4.01B	5.61B	4.88B	5.67B	5.61B
OpEx % of Revenue	0.29%	0.36%	0.28%	0.27%	0.28%	0.34%	0.31%	0.3%	0.37%	0.38%
Selling, General & Admin	2.18B	2.5B	2.58B	2.44B	2.56B	3.34B	4.53B	4.18B	4.65B	4.43B
SG&A % of Revenue	0.23%	0.23%	0.22%	0.21%	0.22%	0.28%	0.25%	0.26%	0.3%	0.3%
Research & Development	671.9M	826.8M	783.3M	704.5M	639.9M	512.6M	681M	662.2M	805.2M	808.7M
R&D % of Revenue	0.07%	0.07%	0.07%	0.06%	0.06%	0.04%	0.04%	0.04%	0.05%	0.05%
Other Operating Expenses	-97.4M	672.5M	-13.1M	-49.5M	-21.4M	150.3M	399.3M	40.8M	217.1M	379.2M
Operating Income+	1.46B	699.2M	1.44B	905.6M	715.5M	-210.8M	-34M	1.61B	766.2M	10.1M
Operating Margin %	0.15%	0.06%	0.12%	0.08%	0.06%	-0.02%	-0%	0.1%	0.05%	0%
Operating Income Growth %	0.08%	-0.52%	1.06%	-0.37%	-0.21%	-1.29%	0.84%	48.5%	-0.53%	-0.99%
EBITDA+	2.49B	2.22B	3.24B	3.02B	2.73B	2.01B	4.47B	4.64B	3.51B	2.9B
EBITDA Margin %	0.26%	0.2%	0.27%	0.26%	0.24%	0.17%	0.25%	0.29%	0.23%	0.2%
EBITDA Growth %	0.3%	-0.11%	0.46%	-0.07%	-0.09%	-0.27%	1.23%	0.04%	-0.24%	-0.17%
D&A (Non-Cash Add-back)	1.03B	1.52B	1.81B	2.11B	2.02B	2.22B	4.51B	3.03B	2.74B	2.89B
EBIT	1.25B	576.5M	1.44B	840.7M	671.7M	-223.4M	-28.2M	3.41B	776M	-73.2M
Net Interest Income+	-336.4M	-442.5M	-534.6M	-542.3M	-517.3M	-497.8M	-636.2M	-592.4M	-573.1M	-550M
Interest Income	0	12.3M	0	0	0	0	0	0	0	0
Interest Expense	336.4M	454.8M	534.6M	542.3M	517.3M	497.8M	636.2M	592.4M	573.1M	550M
Other Income/Expense	-545.5M	-577.5M	-534.2M	-607.2M	-561.1M	-510.4M	-630.4M	1.2B	-563.3M	-633.3M
Pretax Income+	915.4M	121.7M	903M	298.4M	154.4M	-721.2M	-664.4M	2.81B	202.9M	-623.2M
Pretax Margin %	0.1%	0.01%	0.08%	0.03%	0.01%	-0.06%	-0.04%	0.17%	0.01%	-0.04%
Income Tax+	67.7M	-358.3M	207M	-54.1M	137.6M	-51.3M	604.7M	734.6M	148.2M	11M
Effective Tax Rate %	0.93%	3.94%	0.77%	1.18%	0.11%	0.93%	1.91%	0.74%	0.27%	1.02%
Net Income+	847.6M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Net Margin %	0.09%	0.04%	0.06%	0.03%	0%	-0.06%	-0.07%	0.13%	0%	-0.04%
Net Income Growth %	-0.09%	-0.43%	0.45%	-0.49%	-0.95%	-40.88%	-0.89%	2.64%	-0.97%	-12.59%
Net Income (Continuing)	847.7M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	1.4M	1.4M	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.70	0.92	1.30	0.68	0.03	-1.11	-1.05	1.71	0.05	-0.53
EPS Growth %	-0.27%	-0.46%	0.41%	-0.48%	-0.96%	-38%	0.05%	2.63%	-0.97%	-12.7%
EPS (Basic)	1.80	0.94	1.30	0.69	0.03	-1.11	-1.05	1.71	0.05	-0.53
Diluted Shares Outstanding	497.4M	520.5M	536.7M	516.5M	516.5M	601.2M	1.21B	1.22B	1.21B	1.19B
Basic Shares Outstanding	497.4M	520.5M	535.38M	516.5M	560M	601.2M	1.21B	1.21B	1.2B	1.19B
Dividend Payout Ratio	-	-	-	-	-	-	-	0.28%	10.52%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.47B	7.52B	7.21B	6.37B	6.76B	12.87B	10.9B	10.64B	12.98B	9.52B
Cash & Short-Term Investments	1.35B	1.14B	418.9M	449.2M	584.7M	1.05B	935M	1.47B	1.18B	1.09B
Cash Only	1.24B	998.8M	292.1M	388.1M	475.6M	844.4M	701.2M	1.26B	991.9M	734.8M
Short-Term Investments	54M	83.8M	110.6M	57.5M	109.1M	203.5M	233.8M	212.6M	192.5M	355.1M
Accounts Receivable	2.43B	3.02B	3.17B	2.42B	3.06B	4.84B	4.27B	4.14B	4.04B	3.52B
Days Sales Outstanding	94.22	99.36	97.26	77.14	97.08	148	87.06	92.98	95.6	87.22
Inventory	1.95B	2.46B	2.54B	2.58B	2.67B	5.47B	3.98B	3.52B	3.47B	3.85B
Days Inventory Outstanding	136.6	140.53	130.26	126.71	128.22	245.08	117.93	131.54	140.9	154.32
Other Current Assets	601.3M	743.2M	958.8M	791.2M	286.2M	1.24B	1.47B	1.31B	4.13B	913.8M
Total Non-Current Assets+	15.79B	27.2B	28.59B	26.37B	24.5B	48.69B	43.94B	39.39B	34.71B	31.98B
Property, Plant & Equipment	1.98B	2.32B	2.34B	2.17B	2.4B	3.78B	3.48B	3.28B	3.01B	2.92B
Fixed Asset Turnover	4.75x	4.77x	5.09x	5.27x	4.78x	3.16x	5.14x	4.95x	5.13x	5.05x
Goodwill	5.38B	9.23B	10.21B	9.75B	9.59B	12.35B	12.11B	10.43B	9.87B	9.13B
Intangible Assets	7.22B	14.45B	15.25B	13.66B	11.65B	29.68B	26.13B	22.61B	19.18B	17.07B
Long-Term Investments	475.5M	396.4M	226M	138.7M	92.2M	47.9M	81.4M	1.09B	1.14B	1.35B
Other Non-Current Assets	276M	172.2M	79.6M	73.7M	58.2M	676M	798.5M	1.05B	821.1M	754M
Total Assets+	22.27B	34.73B	35.81B	32.73B	31.26B	61.55B	54.84B	50.02B	47.69B	41.5B
Asset Turnover	0.42x	0.32x	0.33x	0.35x	0.37x	0.19x	0.33x	0.33x	0.32x	0.36x
Asset Growth %	0.41%	0.56%	0.03%	-0.09%	-0.05%	0.97%	-0.11%	-0.09%	-0.05%	-0.13%
Total Current Liabilities+	4.12B	5.04B	6.39B	4.59B	5.57B	10.56B	9.88B	6.75B	7.78B	5.78B
Accounts Payable	1.11B	1.35B	1.45B	1.24B	1.06B	1.35B	1.06B	1.16B	1.38B	1.36B
Days Payables Outstanding	77.69	77.13	74.41	61.13	50.98	60.27	31.31	43.28	56.1	54.27
Short-Term Debt	1B	269.7M	1.8B	657.1M	1.46B	3.41B	3.35B	1.25B	1.93B	600K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.55B	2.92B	2.62B	2.29B	832.8M	2.22B	1.41B	1.24B	1.41B	1.34B
Current Ratio	1.57x	1.49x	1.13x	1.39x	1.21x	1.22x	1.10x	1.58x	1.67x	1.65x
Quick Ratio	1.10x	1.01x	0.73x	0.83x	0.73x	0.70x	0.70x	1.05x	1.22x	0.98x
Cash Conversion Cycle	153.13	162.77	153.12	142.73	174.32	332.81	173.68	181.25	180.4	187.27
Total Non-Current Liabilities+	8.38B	18.57B	16.11B	15.98B	13.8B	28.04B	24.47B	22.2B	19.44B	17.09B
Long-Term Debt	6.3B	15.2B	12.87B	13.16B	11.21B	22.43B	19.72B	18.02B	16.19B	14.04B
Capital Lease Obligations	0	0	0	0	175.7M	229.5M	200.9M	181.4M	165.4M	179.3M
Deferred Tax Liabilities	718.1M	2.01B	2.01B	1.72B	1.63B	3.12B	2.81B	2.43B	1.74B	1.11B
Other Non-Current Liabilities	1.37B	1.36B	1.24B	1.1B	785.1M	2.25B	1.73B	1.58B	1.35B	1.76B
Total Liabilities	12.5B	23.61B	22.5B	20.57B	19.37B	38.6B	34.35B	28.95B	27.22B	22.87B
Total Debt+	7.31B	15.47B	14.66B	13.82B	12.92B	26.16B	23.36B	19.53B	18.37B	14.31B
Net Debt	6.07B	14.47B	14.37B	13.43B	12.45B	25.32B	22.66B	18.27B	17.38B	13.57B
Debt / Equity	0.75x	1.39x	1.10x	1.14x	1.09x	1.14x	1.14x	0.93x	0.90x	0.77x
Debt / EBITDA	2.93x	6.96x	4.52x	4.58x	4.73x	13.05x	5.22x	4.21x	5.24x	4.93x
Net Debt / EBITDA	2.43x	6.51x	4.43x	4.45x	4.55x	12.62x	5.07x	3.93x	4.96x	4.67x
Interest Coverage	4.34x	1.54x	2.69x	1.67x	1.38x	-0.42x	-0.05x	2.73x	1.34x	0.02x
Total Equity+	9.77B	11.12B	13.31B	12.17B	11.88B	22.95B	20.49B	21.07B	20.47B	18.64B
Equity Growth %	1.98%	0.14%	0.2%	-0.09%	-0.02%	0.93%	-0.11%	0.03%	-0.03%	-0.09%
Book Value per Share	19.63	21.36	24.80	23.56	23.01	38.18	16.95	17.31	16.96	15.62
Total Shareholders' Equity	9.76B	11.12B	13.31B	12.17B	11.88B	22.95B	20.49B	21.07B	20.47B	18.64B
Common Stock	5.5M	6M	6M	6M	6.1M	12.1M	12.1M	12.1M	12.2M	12.3M
Retained Earnings	4.46B	4.94B	5.64B	6.01B	6.03B	5.36B	3.69B	5.18B	4.64B	3.42B
Treasury Stock	-67.5M	-67.5M	-567.7M	-999.7M	-999.7M	0	0	0	-251.8M	-504.3M
Accumulated OCI	-1.76B	-2.26B	-361.2M	-1.44B	-1.8B	-858M	-1.74B	-2.76B	-2.75B	-3.21B
Minority Interest	1.4M	1.4M	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.01B	2.05B	2.06B	2.34B	1.8B	1.23B	3.02B	3B	2.8B	2.3B
Operating CF Margin %	0.21%	0.18%	0.17%	0.2%	0.16%	0.1%	0.17%	0.18%	0.18%	0.16%
Operating CF Growth %	0.98%	0.02%	0.01%	0.13%	-0.23%	-0.32%	1.45%	-0.01%	-0.07%	-0.18%
Net Income	847.6M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Depreciation & Amortization	1.1B	1.49B	1.73B	1.89B	2.02B	2.22B	4.51B	3.03B	2.74B	2.71B
Stock-Based Compensation	92.8M	88.9M	74.7M	-70.6M	56.8M	79.2M	111.2M	116.4M	180.7M	146.1M
Deferred Taxes	-115.9M	-609.5M	-111.4M	-264.3M	-192.6M	-213.2M	675.7M	-25.9M	-387.1M	-767.6M
Other Non-Cash Items	266.5M	922.5M	277.9M	556.6M	411.2M	515.9M	797.4M	-1.28B	922.1M	1.17B
Working Capital Changes	-298.8M	-934.7M	-712M	-385.4M	-507.8M	-696.3M	-1.8B	-922.6M	-711.3M	-318.6M
Change in Receivables	65.8M	-131.8M	-162.2M	340.1M	-20M	78.7M	59.3M	-240.3M	78.6M	300.1M
Change in Inventory	-320.4M	-279.3M	-129.5M	-547.6M	-512.9M	-741.9M	-427.6M	-259.5M	-613.3M	-723.4M
Change in Payables	131.8M	87.7M	14.4M	220.3M	-96.3M	-82.7M	-70.4M	170.2M	314.7M	36M
Cash from Investing+	-1.57B	-7.68B	-976.4M	-1.21B	-525.4M	-301.1M	-117.8M	1.47B	-764.1M	1.8B
Capital Expenditures	-362.9M	-390.4M	-275.9M	-252.1M	-406M	-681.2M	-509.4M	-489.4M	-377M	-326M
CapEx % of Revenue	0.04%	0.04%	0.02%	0.02%	0.04%	0.06%	0.03%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-513.7M	-497.5M	-533.5M	-892.4M	28M	22.1M	115M	1.96B	280.6M	2.48B
Cash from Financing+	604.8M	5.34B	-1.89B	-1.09B	-1.17B	-605.7M	-3.01B	-3.88B	-2.3B	-4.33B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-399M	-581.6M	-575.6M	-574.8M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	7.4M	-152.1M	-33.4M	-27.2M	-66.1M	-205M	-496.5M	-19.5M	-229.8M	205.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.65B	1.66B	1.79B	2.09B	1.4B	550.6M	2.51B	2.51B	2.33B	1.98B
FCF Margin %	0.17%	0.15%	0.15%	0.18%	0.12%	0.05%	0.14%	0.15%	0.15%	0.13%
FCF Growth %	1.39%	0.01%	0.08%	0.17%	-0.33%	-0.61%	3.55%	0%	-0.07%	-0.15%
FCF per Share	3.31	3.18	3.33	4.05	2.71	0.92	2.07	2.06	1.93	1.66
FCF Conversion (FCF/Net Income)	2.37x	4.27x	2.97x	6.64x	107.36x	-1.84x	-2.38x	1.44x	51.18x	-3.63x
Interest Paid	254.7M	357.2M	474M	460.8M	470.6M	555.4M	684.8M	642.5M	611.6M	561.1M
Taxes Paid	302.9M	285.6M	285.7M	228.6M	278.6M	324.4M	641.7M	735.2M	570.9M	514M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	13%	4.6%	5.7%	2.77%	0.14%	-3.85%	-5.84%	10%	0.26%	-3.24%
Return on Invested Capital (ROIC)	8.01%	2.53%	4.05%	2.55%	2.15%	-0.44%	-0.06%	2.94%	1.49%	0.02%
Gross Margin	44.71%	42.4%	40.17%	35%	33.89%	31.78%	31.17%	39.95%	41.74%	38.15%
Net Margin	8.99%	4.33%	5.85%	3.08%	0.15%	-5.61%	-7.1%	12.78%	0.35%	-4.3%
Debt / Equity	0.75x	1.39x	1.10x	1.14x	1.09x	1.14x	1.14x	0.93x	0.90x	0.77x
Interest Coverage	4.34x	1.54x	2.69x	1.67x	1.38x	-0.42x	-0.05x	2.73x	1.34x	0.02x
FCF Conversion	2.37x	4.27x	2.97x	6.64x	107.36x	-1.84x	-2.38x	1.44x	51.18x	-3.63x
Revenue Growth	22.15%	17.47%	7.5%	-3.98%	0.58%	3.87%	49.73%	-9.08%	-5.14%	-4.46%

Revenue by Segment

	2020	2021	2022	2023	2024
Brands	5.23B	10.84B	9.89B	9.8B	9.2B
Brands Growth	-	107.10%	-8.78%	-0.90%	-6.12%
Generics	5.29B	5.63B	5.02B	5.59B	5.49B
Generics Growth	-	6.44%	-10.93%	11.42%	-1.71%
Complex GX and Biosimilars	1.3B	1.34B	1.31B	-	-
Complex GX and Biosimilars Growth	-	3.60%	-2.14%	-	-

Revenue by Geography

	2020	2021	2022	2023	2024
Developed Markets	8.51B	10.43B	9.77B	9.25B	8.96B
Developed Markets Growth	-	22.53%	-6.33%	-5.29%	-3.14%
Emerging Markets	1.85B	3.14B	2.62B	2.55B	2.26B
Emerging Markets Growth	-	69.64%	-16.83%	-2.45%	-11.41%
China	259.9M	2.21B	2.2B	2.16B	2.17B
China Growth	-	751.40%	-0.52%	-1.85%	0.34%
Japan, Australia and New Zealand	1.2B	2.03B	1.63B	1.42B	1.35B
Japan, Australia and New Zealand Growth	-	69.61%	-19.48%	-12.74%	-5.25%

Frequently Asked Questions

Growth & Financials

Viatris Inc. (VTRS) reported $14.12B in revenue for fiscal year 2024. This represents a 130% increase from $6.13B in 2011.

Viatris Inc. (VTRS) saw revenue decline by 4.5% over the past year.

Viatris Inc. (VTRS) reported a net loss of $3.69B for fiscal year 2024.

Dividend & Returns

Yes, Viatris Inc. (VTRS) pays a dividend with a yield of 3.75%. This makes it attractive for income-focused investors.

Viatris Inc. (VTRS) has a return on equity (ROE) of -3.2%. Negative ROE indicates the company is unprofitable.

Viatris Inc. (VTRS) generated $1.60B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Viatris Inc. (VTRS) 10-Year Financial Performance & Capital Metrics

VTRS • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

Revenue $14.74B -4.5%
EBITDA $2.9B -17.2%
Net Income -$634M -1259.4%
EPS (Diluted) -0.53 -1270.0%
Gross Margin 38.15% -8.6%
EBITDA Margin 19.7% -13.3%
Operating Margin 0.07% -98.6%
Net Margin -4.3% -1313.4%
ROE -3.24% -1331.5%
ROIC 0.02% -98.5%
Debt/Equity 0.77 -14.5%
Interest Coverage 0.02 -98.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy dividend yield of 3.8%
✓Trading near 52-week high
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak 3Y average ROE of 2.3%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.68%

5Y5.09%

3Y-6.25%

TTM-6.14%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-317.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-319.92%

ROCE

10Y Avg2.87%

5Y Avg0.98%

3Y Avg1.84%

Latest0.03%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.43B	11.08B	11.91B	11.43B	11.5B	11.95B	17.89B	16.26B	15.43B	14.74B
Revenue Growth %	0.22%	0.17%	0.08%	-0.04%	0.01%	0.04%	0.5%	-0.09%	-0.05%	-0.04%
Cost of Goods Sold+	5.21B	6.38B	7.12B	7.43B	7.6B	8.15B	12.31B	9.77B	8.99B	9.12B
COGS % of Revenue	0.55%	0.58%	0.6%	0.65%	0.66%	0.68%	0.69%	0.6%	0.58%	0.62%
Gross Profit+	4.22B	4.7B	4.78B	4B	3.9B	3.8B	5.58B	6.5B	6.44B	5.62B
Gross Margin %	0.45%	0.42%	0.4%	0.35%	0.34%	0.32%	0.31%	0.4%	0.42%	0.38%
Gross Profit Growth %	0.2%	0.11%	0.02%	-0.16%	-0.03%	-0.03%	0.47%	0.17%	-0.01%	-0.13%
Operating Expenses+	2.76B	4B	3.35B	3.1B	3.18B	4.01B	5.61B	4.88B	5.67B	5.61B
OpEx % of Revenue	0.29%	0.36%	0.28%	0.27%	0.28%	0.34%	0.31%	0.3%	0.37%	0.38%
Selling, General & Admin	2.18B	2.5B	2.58B	2.44B	2.56B	3.34B	4.53B	4.18B	4.65B	4.43B
SG&A % of Revenue	0.23%	0.23%	0.22%	0.21%	0.22%	0.28%	0.25%	0.26%	0.3%	0.3%
Research & Development	671.9M	826.8M	783.3M	704.5M	639.9M	512.6M	681M	662.2M	805.2M	808.7M
R&D % of Revenue	0.07%	0.07%	0.07%	0.06%	0.06%	0.04%	0.04%	0.04%	0.05%	0.05%
Other Operating Expenses	-97.4M	672.5M	-13.1M	-49.5M	-21.4M	150.3M	399.3M	40.8M	217.1M	379.2M
Operating Income+	1.46B	699.2M	1.44B	905.6M	715.5M	-210.8M	-34M	1.61B	766.2M	10.1M
Operating Margin %	0.15%	0.06%	0.12%	0.08%	0.06%	-0.02%	-0%	0.1%	0.05%	0%
Operating Income Growth %	0.08%	-0.52%	1.06%	-0.37%	-0.21%	-1.29%	0.84%	48.5%	-0.53%	-0.99%
EBITDA+	2.49B	2.22B	3.24B	3.02B	2.73B	2.01B	4.47B	4.64B	3.51B	2.9B
EBITDA Margin %	0.26%	0.2%	0.27%	0.26%	0.24%	0.17%	0.25%	0.29%	0.23%	0.2%
EBITDA Growth %	0.3%	-0.11%	0.46%	-0.07%	-0.09%	-0.27%	1.23%	0.04%	-0.24%	-0.17%
D&A (Non-Cash Add-back)	1.03B	1.52B	1.81B	2.11B	2.02B	2.22B	4.51B	3.03B	2.74B	2.89B
EBIT	1.25B	576.5M	1.44B	840.7M	671.7M	-223.4M	-28.2M	3.41B	776M	-73.2M
Net Interest Income+	-336.4M	-442.5M	-534.6M	-542.3M	-517.3M	-497.8M	-636.2M	-592.4M	-573.1M	-550M
Interest Income	0	12.3M	0	0	0	0	0	0	0	0
Interest Expense	336.4M	454.8M	534.6M	542.3M	517.3M	497.8M	636.2M	592.4M	573.1M	550M
Other Income/Expense	-545.5M	-577.5M	-534.2M	-607.2M	-561.1M	-510.4M	-630.4M	1.2B	-563.3M	-633.3M
Pretax Income+	915.4M	121.7M	903M	298.4M	154.4M	-721.2M	-664.4M	2.81B	202.9M	-623.2M
Pretax Margin %	0.1%	0.01%	0.08%	0.03%	0.01%	-0.06%	-0.04%	0.17%	0.01%	-0.04%
Income Tax+	67.7M	-358.3M	207M	-54.1M	137.6M	-51.3M	604.7M	734.6M	148.2M	11M
Effective Tax Rate %	0.93%	3.94%	0.77%	1.18%	0.11%	0.93%	1.91%	0.74%	0.27%	1.02%
Net Income+	847.6M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Net Margin %	0.09%	0.04%	0.06%	0.03%	0%	-0.06%	-0.07%	0.13%	0%	-0.04%
Net Income Growth %	-0.09%	-0.43%	0.45%	-0.49%	-0.95%	-40.88%	-0.89%	2.64%	-0.97%	-12.59%
Net Income (Continuing)	847.7M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	1.4M	1.4M	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.70	0.92	1.30	0.68	0.03	-1.11	-1.05	1.71	0.05	-0.53
EPS Growth %	-0.27%	-0.46%	0.41%	-0.48%	-0.96%	-38%	0.05%	2.63%	-0.97%	-12.7%
EPS (Basic)	1.80	0.94	1.30	0.69	0.03	-1.11	-1.05	1.71	0.05	-0.53
Diluted Shares Outstanding	497.4M	520.5M	536.7M	516.5M	516.5M	601.2M	1.21B	1.22B	1.21B	1.19B
Basic Shares Outstanding	497.4M	520.5M	535.38M	516.5M	560M	601.2M	1.21B	1.21B	1.2B	1.19B
Dividend Payout Ratio	-	-	-	-	-	-	-	0.28%	10.52%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.47B	7.52B	7.21B	6.37B	6.76B	12.87B	10.9B	10.64B	12.98B	9.52B
Cash & Short-Term Investments	1.35B	1.14B	418.9M	449.2M	584.7M	1.05B	935M	1.47B	1.18B	1.09B
Cash Only	1.24B	998.8M	292.1M	388.1M	475.6M	844.4M	701.2M	1.26B	991.9M	734.8M
Short-Term Investments	54M	83.8M	110.6M	57.5M	109.1M	203.5M	233.8M	212.6M	192.5M	355.1M
Accounts Receivable	2.43B	3.02B	3.17B	2.42B	3.06B	4.84B	4.27B	4.14B	4.04B	3.52B
Days Sales Outstanding	94.22	99.36	97.26	77.14	97.08	148	87.06	92.98	95.6	87.22
Inventory	1.95B	2.46B	2.54B	2.58B	2.67B	5.47B	3.98B	3.52B	3.47B	3.85B
Days Inventory Outstanding	136.6	140.53	130.26	126.71	128.22	245.08	117.93	131.54	140.9	154.32
Other Current Assets	601.3M	743.2M	958.8M	791.2M	286.2M	1.24B	1.47B	1.31B	4.13B	913.8M
Total Non-Current Assets+	15.79B	27.2B	28.59B	26.37B	24.5B	48.69B	43.94B	39.39B	34.71B	31.98B
Property, Plant & Equipment	1.98B	2.32B	2.34B	2.17B	2.4B	3.78B	3.48B	3.28B	3.01B	2.92B
Fixed Asset Turnover	4.75x	4.77x	5.09x	5.27x	4.78x	3.16x	5.14x	4.95x	5.13x	5.05x
Goodwill	5.38B	9.23B	10.21B	9.75B	9.59B	12.35B	12.11B	10.43B	9.87B	9.13B
Intangible Assets	7.22B	14.45B	15.25B	13.66B	11.65B	29.68B	26.13B	22.61B	19.18B	17.07B
Long-Term Investments	475.5M	396.4M	226M	138.7M	92.2M	47.9M	81.4M	1.09B	1.14B	1.35B
Other Non-Current Assets	276M	172.2M	79.6M	73.7M	58.2M	676M	798.5M	1.05B	821.1M	754M
Total Assets+	22.27B	34.73B	35.81B	32.73B	31.26B	61.55B	54.84B	50.02B	47.69B	41.5B
Asset Turnover	0.42x	0.32x	0.33x	0.35x	0.37x	0.19x	0.33x	0.33x	0.32x	0.36x
Asset Growth %	0.41%	0.56%	0.03%	-0.09%	-0.05%	0.97%	-0.11%	-0.09%	-0.05%	-0.13%
Total Current Liabilities+	4.12B	5.04B	6.39B	4.59B	5.57B	10.56B	9.88B	6.75B	7.78B	5.78B
Accounts Payable	1.11B	1.35B	1.45B	1.24B	1.06B	1.35B	1.06B	1.16B	1.38B	1.36B
Days Payables Outstanding	77.69	77.13	74.41	61.13	50.98	60.27	31.31	43.28	56.1	54.27
Short-Term Debt	1B	269.7M	1.8B	657.1M	1.46B	3.41B	3.35B	1.25B	1.93B	600K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.55B	2.92B	2.62B	2.29B	832.8M	2.22B	1.41B	1.24B	1.41B	1.34B
Current Ratio	1.57x	1.49x	1.13x	1.39x	1.21x	1.22x	1.10x	1.58x	1.67x	1.65x
Quick Ratio	1.10x	1.01x	0.73x	0.83x	0.73x	0.70x	0.70x	1.05x	1.22x	0.98x
Cash Conversion Cycle	153.13	162.77	153.12	142.73	174.32	332.81	173.68	181.25	180.4	187.27
Total Non-Current Liabilities+	8.38B	18.57B	16.11B	15.98B	13.8B	28.04B	24.47B	22.2B	19.44B	17.09B
Long-Term Debt	6.3B	15.2B	12.87B	13.16B	11.21B	22.43B	19.72B	18.02B	16.19B	14.04B
Capital Lease Obligations	0	0	0	0	175.7M	229.5M	200.9M	181.4M	165.4M	179.3M
Deferred Tax Liabilities	718.1M	2.01B	2.01B	1.72B	1.63B	3.12B	2.81B	2.43B	1.74B	1.11B
Other Non-Current Liabilities	1.37B	1.36B	1.24B	1.1B	785.1M	2.25B	1.73B	1.58B	1.35B	1.76B
Total Liabilities	12.5B	23.61B	22.5B	20.57B	19.37B	38.6B	34.35B	28.95B	27.22B	22.87B
Total Debt+	7.31B	15.47B	14.66B	13.82B	12.92B	26.16B	23.36B	19.53B	18.37B	14.31B
Net Debt	6.07B	14.47B	14.37B	13.43B	12.45B	25.32B	22.66B	18.27B	17.38B	13.57B
Debt / Equity	0.75x	1.39x	1.10x	1.14x	1.09x	1.14x	1.14x	0.93x	0.90x	0.77x
Debt / EBITDA	2.93x	6.96x	4.52x	4.58x	4.73x	13.05x	5.22x	4.21x	5.24x	4.93x
Net Debt / EBITDA	2.43x	6.51x	4.43x	4.45x	4.55x	12.62x	5.07x	3.93x	4.96x	4.67x
Interest Coverage	4.34x	1.54x	2.69x	1.67x	1.38x	-0.42x	-0.05x	2.73x	1.34x	0.02x
Total Equity+	9.77B	11.12B	13.31B	12.17B	11.88B	22.95B	20.49B	21.07B	20.47B	18.64B
Equity Growth %	1.98%	0.14%	0.2%	-0.09%	-0.02%	0.93%	-0.11%	0.03%	-0.03%	-0.09%
Book Value per Share	19.63	21.36	24.80	23.56	23.01	38.18	16.95	17.31	16.96	15.62
Total Shareholders' Equity	9.76B	11.12B	13.31B	12.17B	11.88B	22.95B	20.49B	21.07B	20.47B	18.64B
Common Stock	5.5M	6M	6M	6M	6.1M	12.1M	12.1M	12.1M	12.2M	12.3M
Retained Earnings	4.46B	4.94B	5.64B	6.01B	6.03B	5.36B	3.69B	5.18B	4.64B	3.42B
Treasury Stock	-67.5M	-67.5M	-567.7M	-999.7M	-999.7M	0	0	0	-251.8M	-504.3M
Accumulated OCI	-1.76B	-2.26B	-361.2M	-1.44B	-1.8B	-858M	-1.74B	-2.76B	-2.75B	-3.21B
Minority Interest	1.4M	1.4M	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.01B	2.05B	2.06B	2.34B	1.8B	1.23B	3.02B	3B	2.8B	2.3B
Operating CF Margin %	0.21%	0.18%	0.17%	0.2%	0.16%	0.1%	0.17%	0.18%	0.18%	0.16%
Operating CF Growth %	0.98%	0.02%	0.01%	0.13%	-0.23%	-0.32%	1.45%	-0.01%	-0.07%	-0.18%
Net Income	847.6M	480M	696M	352.5M	16.8M	-669.9M	-1.27B	2.08B	54.7M	-634.2M
Depreciation & Amortization	1.1B	1.49B	1.73B	1.89B	2.02B	2.22B	4.51B	3.03B	2.74B	2.71B
Stock-Based Compensation	92.8M	88.9M	74.7M	-70.6M	56.8M	79.2M	111.2M	116.4M	180.7M	146.1M
Deferred Taxes	-115.9M	-609.5M	-111.4M	-264.3M	-192.6M	-213.2M	675.7M	-25.9M	-387.1M	-767.6M
Other Non-Cash Items	266.5M	922.5M	277.9M	556.6M	411.2M	515.9M	797.4M	-1.28B	922.1M	1.17B
Working Capital Changes	-298.8M	-934.7M	-712M	-385.4M	-507.8M	-696.3M	-1.8B	-922.6M	-711.3M	-318.6M
Change in Receivables	65.8M	-131.8M	-162.2M	340.1M	-20M	78.7M	59.3M	-240.3M	78.6M	300.1M
Change in Inventory	-320.4M	-279.3M	-129.5M	-547.6M	-512.9M	-741.9M	-427.6M	-259.5M	-613.3M	-723.4M
Change in Payables	131.8M	87.7M	14.4M	220.3M	-96.3M	-82.7M	-70.4M	170.2M	314.7M	36M
Cash from Investing+	-1.57B	-7.68B	-976.4M	-1.21B	-525.4M	-301.1M	-117.8M	1.47B	-764.1M	1.8B
Capital Expenditures	-362.9M	-390.4M	-275.9M	-252.1M	-406M	-681.2M	-509.4M	-489.4M	-377M	-326M
CapEx % of Revenue	0.04%	0.04%	0.02%	0.02%	0.04%	0.06%	0.03%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-513.7M	-497.5M	-533.5M	-892.4M	28M	22.1M	115M	1.96B	280.6M	2.48B
Cash from Financing+	604.8M	5.34B	-1.89B	-1.09B	-1.17B	-605.7M	-3.01B	-3.88B	-2.3B	-4.33B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-399M	-581.6M	-575.6M	-574.8M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	7.4M	-152.1M	-33.4M	-27.2M	-66.1M	-205M	-496.5M	-19.5M	-229.8M	205.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.65B	1.66B	1.79B	2.09B	1.4B	550.6M	2.51B	2.51B	2.33B	1.98B
FCF Margin %	0.17%	0.15%	0.15%	0.18%	0.12%	0.05%	0.14%	0.15%	0.15%	0.13%
FCF Growth %	1.39%	0.01%	0.08%	0.17%	-0.33%	-0.61%	3.55%	0%	-0.07%	-0.15%
FCF per Share	3.31	3.18	3.33	4.05	2.71	0.92	2.07	2.06	1.93	1.66
FCF Conversion (FCF/Net Income)	2.37x	4.27x	2.97x	6.64x	107.36x	-1.84x	-2.38x	1.44x	51.18x	-3.63x
Interest Paid	254.7M	357.2M	474M	460.8M	470.6M	555.4M	684.8M	642.5M	611.6M	561.1M
Taxes Paid	302.9M	285.6M	285.7M	228.6M	278.6M	324.4M	641.7M	735.2M	570.9M	514M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	13%	4.6%	5.7%	2.77%	0.14%	-3.85%	-5.84%	10%	0.26%	-3.24%
Return on Invested Capital (ROIC)	8.01%	2.53%	4.05%	2.55%	2.15%	-0.44%	-0.06%	2.94%	1.49%	0.02%
Gross Margin	44.71%	42.4%	40.17%	35%	33.89%	31.78%	31.17%	39.95%	41.74%	38.15%
Net Margin	8.99%	4.33%	5.85%	3.08%	0.15%	-5.61%	-7.1%	12.78%	0.35%	-4.3%
Debt / Equity	0.75x	1.39x	1.10x	1.14x	1.09x	1.14x	1.14x	0.93x	0.90x	0.77x
Interest Coverage	4.34x	1.54x	2.69x	1.67x	1.38x	-0.42x	-0.05x	2.73x	1.34x	0.02x
FCF Conversion	2.37x	4.27x	2.97x	6.64x	107.36x	-1.84x	-2.38x	1.44x	51.18x	-3.63x
Revenue Growth	22.15%	17.47%	7.5%	-3.98%	0.58%	3.87%	49.73%	-9.08%	-5.14%	-4.46%

Revenue by Segment

	2020	2021	2022	2023	2024
Brands	5.23B	10.84B	9.89B	9.8B	9.2B
Brands Growth	-	107.10%	-8.78%	-0.90%	-6.12%
Generics	5.29B	5.63B	5.02B	5.59B	5.49B
Generics Growth	-	6.44%	-10.93%	11.42%	-1.71%
Complex GX and Biosimilars	1.3B	1.34B	1.31B	-	-
Complex GX and Biosimilars Growth	-	3.60%	-2.14%	-	-

Revenue by Geography

	2020	2021	2022	2023	2024
Developed Markets	8.51B	10.43B	9.77B	9.25B	8.96B
Developed Markets Growth	-	22.53%	-6.33%	-5.29%	-3.14%
Emerging Markets	1.85B	3.14B	2.62B	2.55B	2.26B
Emerging Markets Growth	-	69.64%	-16.83%	-2.45%	-11.41%
China	259.9M	2.21B	2.2B	2.16B	2.17B
China Growth	-	751.40%	-0.52%	-1.85%	0.34%
Japan, Australia and New Zealand	1.2B	2.03B	1.63B	1.42B	1.35B
Japan, Australia and New Zealand Growth	-	69.61%	-19.48%	-12.74%	-5.25%

Frequently Asked Questions

Growth & Financials

Viatris Inc. (VTRS) reported $14.12B in revenue for fiscal year 2024. This represents a 130% increase from $6.13B in 2011.

Viatris Inc. (VTRS) saw revenue decline by 4.5% over the past year.

Viatris Inc. (VTRS) reported a net loss of $3.69B for fiscal year 2024.

Dividend & Returns

Yes, Viatris Inc. (VTRS) pays a dividend with a yield of 3.75%. This makes it attractive for income-focused investors.

Viatris Inc. (VTRS) has a return on equity (ROE) of -3.2%. Negative ROE indicates the company is unprofitable.

Viatris Inc. (VTRS) generated $1.60B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.